牛牛AI助理已提取核心訊息
Merck & Co. Inc. officer Robert M. Davis is set to sell 150,000 shares of the company's common stock, with an aggregate market value of approximately $18,872,130, on February 13, 2024. The shares to be sold were acquired through the exercise of options under a registered plan, with two significant acquisitions on May 1, 2020, and May 4, 2021, totaling 41,509 and 108,491 shares respectively. The transactions were part of a structured plan for acquiring securities directly from the issuer. There have been no sales of securities reported in the past three months prior to this notice.
Merck & Co. Inc. officer Robert M. Davis is set to sell 150,000 shares of the company's common stock, with an aggregate market value of approximately $18,872,130, on February 13, 2024. The shares to be sold were acquired through the exercise of options under a registered plan, with two significant acquisitions on May 1, 2020, and May 4, 2021, totaling 41,509 and 108,491 shares respectively. The transactions were part of a structured plan for acquiring securities directly from the issuer. There have been no sales of securities reported in the past three months prior to this notice.
默沙東公司公司高管羅伯特·戴維斯定於2024年2月13日出售該公司15萬股普通股，總市值約爲18,872,130美元。待出售的股票是通過行使註冊計劃下的期權收購的，兩次重大收購分別於2020年5月1日和2021年5月4日進行，總額分別爲41,509股和108,491股。這些交易是直接從發行人那裏收購證券的結構化計劃的一部分。在本通知發佈前的過去三個月中，沒有報告任何證券的銷售情況。
默沙東公司公司高管羅伯特·戴維斯定於2024年2月13日出售該公司15萬股普通股，總市值約爲18,872,130美元。待出售的股票是通過行使註冊計劃下的期權收購的，兩次重大收購分別於2020年5月1日和2021年5月4日進行，總額分別爲41,509股和108,491股。這些交易是直接從發行人那裏收購證券的結構化計劃的一部分。在本通知發佈前的過去三個月中，沒有報告任何證券的銷售情況。
有用
沒用